Charles River Unveils 2030 Targets: 5-7% Growth, ~24% Margin, $300M Savings Plan
CRL sits 92% above its 52-week low of $144.26.
Summary
Charles River's Investor Day introduces a refreshed strategy with concrete long-term financial targets through 2030: 5-7% organic revenue CAGR, ~24% non-GAAP operating margin, and low-double-digit EPS growth. The Create the Future program is expected to deliver over $300 million in cumulative savings from 2027-2030, and bioanalysis revenue is targeted to reach ~$450 million by 2030. Management also reaffirmed 2026 guidance at the upper end of ranges, with adjusted EPS expected at the upper end of the $11.15-$11.45 range, citing favorable biopharma demand. These targets provide a clear multi-year growth framework following the Q2 beat and raised outlook in August, and the market will likely react to the specificity of the margin expansion and savings plan.
At the time of this announcement, CRL was trading at $277.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $144.26 to $303.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.